Towards Automation of Germline Variant Curation in Clinical Cancer Genetics
暂无分享,去创建一个
Zarina Shameer | Kenneth Offit | Mark Robson | Vignesh Ravichandran | Karen Cadoo | Steven Lipkin | Zsofia Stadler | Joseph Vijai | K. Offit | S. Lipkin | J. Vijai | M. Robson | Z. Stadler | K. Cadoo | Vignesh Ravichandran | Y. Kemel | D. Mandelker | Liying Zhang | M. Walsh | Liying Zhang | Yelena Kemel | Michael Walsh | Diana Mandelker | Zarina Shameer | Yelena Kernel
[1] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Børresen-Dale,et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. , 2001, Journal of the National Cancer Institute.
[3] Genica,et al. Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium , 2006 .
[4] Paul D.P. Pharoah,et al. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. , 2007, Journal of the National Cancer Institute.
[5] Georgia Chenevix-Trench,et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.
[6] Amit Kumar Sharma,et al. The Curation of Genetic Variants: Difficulties and Possible Solutions , 2012, Genom. Proteom. Bioinform..
[7] Sue Healey,et al. ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.
[8] Peter Kraft,et al. COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration , 2013, Breast Cancer Research.
[9] P. Dundr,et al. The PALB2 Gene Is a Strong Candidate for Clinical Testing in BRCA1- and BRCA2-Negative Hereditary Breast Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[10] F. Couch,et al. Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.
[11] Jay Shendure,et al. Saturation Editing of Genomic Regions by Multiplex Homology-Directed Repair , 2014, Nature.
[12] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[13] Li Ding,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.
[14] Yuya Kobayashi,et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. , 2015, JAMA oncology.
[15] Heidi L Rehm,et al. ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.
[16] Dong Liang,et al. PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS , 2016 .
[17] G. Jarvik,et al. Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. , 2016, American journal of human genetics.
[18] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[19] Shawn Rynearson,et al. ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variants , 2017, Genome Medicine.
[20] M. Daly,et al. A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. , 2016, Cancer discovery.
[21] Ahmet Zehir,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.
[22] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[23] Steven N. Hart,et al. Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes , 2016, Briefings Bioinform..
[24] Matthew S. Lebo,et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.
[25] Christophe Béroud,et al. BRCA Share: A Collection of Clinical BRCA Gene Variants , 2016, Human mutation.
[26] Robert C. Green,et al. Erratum: Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium (American Journal of Human Genetics (2016) 98(6) (1067–1076) (S0002929716300593) (10.1016/j.ajhg.2016.03.024)) , 2016 .
[27] Vijai Joseph,et al. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Raymond M. Moore,et al. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. , 2016, American journal of human genetics.
[29] F. Couch,et al. Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants. , 2016 .
[30] Robert J. Lonigro,et al. Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.
[31] Keith Nykamp,et al. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria , 2017, Genetics in Medicine.
[32] Maitreya J. Dunham,et al. Variant Interpretation: Functional Assays to the Rescue. , 2017, American journal of human genetics.
[33] P. Kantoff,et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.
[34] K. Offit. Multigene Testing for Hereditary Cancer: When, Why, and How. , 2017, The Journal of the National Comprehensive Cancer Network.
[35] Soma Das,et al. Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.
[36] Quan Li,et al. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.
[37] Raymond M. Moore,et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.
[38] Joseph D. Janizek,et al. Accurate classification of BRCA1 variants with saturation genome editing , 2018, Nature.
[39] Risha Govind,et al. CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation , 2018, Genetics in Medicine.
[40] Birgit Funke,et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.